Empowering innovation.
Delivering opportunity.

Our mission is to deliver medicines
that make a difference for people with life-altering diseases.

Learn More

We are focused on advancing a diversified portfolio of next-generation immuno-oncology therapies to transform cancer treatment and extend survival for patients with hard-to-treat tumors.

Now Available In The U.S.

LOQTORZI (toripalimab-tpzi) is the first and only FDA-approved therapy for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) in combination with chemotherapy or as a single agent.

Our Programs

Developing a Portfolio of Immuno-Oncology Drugs to Improve Patient Outcomes

Our pipeline includes multiple clinical stage immuno-oncology drug candidates that target the tumor microenvironment.

View Our Pipeline
Our Clinical Trials

Testing the Safety and Effectiveness of Our I-O Drug Candidates

We have multiple ongoing clinical trials across a range of cancer indications assessing our investigational immuno-oncology therapeutics.

See Clinical Trials

Become part of our talented and passionate organization and make an impact.